Form 4: Tyra Biosciences CEO Todd Harris Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Tyra Biosciences' CEO, Todd Harris, executed multiple sales of common stock between October 15 and October 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Todd Harris, the President and CEO of Tyra Biosciences, sold shares of common stock between October 15 and October 17, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted in December 2022.
- On October 15, 2024, 10,035 shares were sold at a weighted average price of $24.3119.
- On October 16, 2024, a total of 33,397 shares were sold in three separate transactions at weighted average prices of $25.2155, $26.2334, and $26.9789.
- On October 17, 2024, a total of 15,394 shares were sold in two separate transactions at weighted average prices of $25.839 and $26.37.
- Following these transactions, Todd Harris directly owns 1,418,647 shares of Tyra Biosciences common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock sales by an insider. It's neutral in tone and doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Sales by company insiders are common and often pre-planned to avoid accusations of trading on non-public information. The use of a 10b5-1 plan provides a legal framework for insiders to sell shares at predetermined times and prices.
Stakeholder Impact
- Shareholders may react to insider selling, although pre-planned sales under Rule 10b5-1 are generally viewed as less concerning.
Key Dates
| Date | Description |
|---|---|
| December 2022 | Date the Rule 10b5-1 trading plan was adopted by Todd Harris. |
| 10/15/2024 | Date of the first reported transaction: sale of 10,035 shares. |
| 10/16/2024 | Date of multiple transactions: sales of 4,900, 24,475 and 3,922 shares. |
| 10/17/2024 | Date of the last reported transaction: sales of 15,194 and 200 shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.